| Literature DB >> 29365313 |
Gabriela M Webb1,2, Shengbin Li3, Gwantwa Mwakalundwa3, Joy M Folkvord4, Justin M Greene1,2, Jason S Reed1,2, Jeffery J Stanton2, Alfred W Legasse2, Theodore Hobbs2, Lauren D Martin2, Byung S Park2, James B Whitney5,6, Emily K Jeng7, Hing C Wong7, Douglas F Nixon8, R Brad Jones8, Elizabeth Connick4, Pamela J Skinner3, Jonah B Sacha1,2.
Abstract
Sequestering of latent HIV in follicular helper T cells within B-cell follicles that largely exclude cytotoxic T cells is a major barrier to cellular immune-based approaches to eradicate HIV. Here, we show that the clinical-grade human interleukin-15 (IL-15) superagonist ALT-803 activates and redirects simian immunodeficiency virus (SIV)-specific CD8+ T cells from the peripheral blood into B-cell follicles. In agreement with the increased trafficking of SIV-specific cytotoxic T cells to sites of cryptic viral replication, lymph nodes of elite controlling macaques contained fewer cells expressing SIV RNA or harboring SIV DNA post-ALT-803 treatment. These data establish ALT-803 as an immunotherapeutic for HIV and other chronic viral pathogens that evade host immunity by persisting in B-cell follicles.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29365313 PMCID： PMC5787870 DOI： 10.1182/bloodadvances.2017012971
Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529